Cell and gene therapy tout promising results, but manufacturing challenges around personalized treatments require industry ...

According to research by nova one advisor, the global cell and gene therapy market size was valued at $18.13 billion in 2023 ...

With the FDA expecting to approve 10–20 Cell and Gene Therapies (CGTs ... and updates in cell therapy regulation The importance of partnerships within the CGT ecosystem Deciding on a commercially ...

The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

The alliance will focus on optimising and enhancing the production process of TCR therapies targeting ... which is instrumental in cell and gene therapy research and development.

Upstream Processing Segment to Dominate the Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process) Based on process, the upstream processing segment accounted for the largest ...

Beam Therapeutics Inc. (NASDAQ:BEAM)’s newly developed automated CD34+ cell process for BEAM-101 manufacturing is expected to revolutionize gene therapy. By increasing process capacity threefold ...

The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...